histopathological grade and high histopathological grade DDL to be 113 months and 48 months, respectively. Further studies are needed to provide evidence on the efficacies of radiotherapy, chemotherapy, and novel therapies in all the varieties of DDL. Novel therapies Several novel therapy regimens for DDL and the more aggressive or otherwise problematic cases of ALT/WDL are currently undergoing clinical trials. A phase II clinical study investigating abemaciclib is underway in patients with pretreated or untreated DDL. Preliminary analysis showed that this inhibitor of the CDK4 and CDK6 genes' product Serine/threonine-specific protein kinase enzymes produced a prolonged median progression-free survival time of 30.4 weeks. A phase III multicenter, randomized, double-blind, placebo-controlled clinical study of abemaciclib is in its active phase and will soon (as stated in July, 2021) begin recruiting 108 individuals with advanced, recurrent, and/or metastatic DDL. The study is sponsored by the Sarcoma Alliance for Research through Collaboration in collaboration with Eli Lilly and Company. Ribociclib, also a CDK4 and CDK6 gene inhibitor, in combination with a mTOR inhibitor, everolimus is in a phase II clinical trial in individuals with advanced DDL or leiomyosarcoma. A phase III registration study (i.e. a large confirmatory study meant to establish an acceptable benefit/safety profile in order to gain regulatory approval for a precisely defined indication) is evaluating the safety and efficacy of milademetan compared to trabectedin in patients with unresectable (i.e., resection is deemed to cause unacceptable morbidity or mortality) or metastatic DDL that has progressed on 1 or more prior systemic therapies, including at least 1 anthracycline-based therapy. The sponsor, Rain Therapeutics Inc, is currently recruiting 160 individuals for the trial. Another phase III clinical trial is investigating the MDM2 inhibitor milademetan versus trabectedin, a blocker of the oncogenic transcription factor FUS-CHOP, in MDM2-overexpressing ALT/WDL and DDL. Milademetan has shown manageable toxicity and some activity resulting in stable disease and/or a few partial responses in DDL. Myxoid liposarcoma Presentation Myxoid liposarcoma (MLS), which includes a type of liposarcoma termed round cell liposarcoma, represents ~30% of all liposarcomas. It has a peak incidence in individuals' fourth and fifth decades with a male predominance in most studies. While uncommon in children and adolescents, MLS is the most common liposarcoma form diagnosed in these age groups. MLS typically presents as a large (1 to 39 cm; average 12 cm), mobile, well-circumscribed, painless mass that developed from 1 week to 15 years prior to diagnosis.